Logo image of VTVT

VTV THERAPEUTICS INC- CL A (VTVT) Stock Fundamental Analysis

NASDAQ:VTVT - Nasdaq - US9183852048 - Common Stock - Currency: USD

15.54  -1.49 (-8.75%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VTVT. VTVT was compared to 556 industry peers in the Biotechnology industry. While VTVT has a great health rating, there are worries on its profitability. VTVT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VTVT has reported negative net income.
VTVT had a negative operating cash flow in the past year.
In the past 5 years VTVT always reported negative net income.
VTVT had a negative operating cash flow in each of the past 5 years.
VTVT Yearly Net Income VS EBIT VS OCF VS FCFVTVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

VTVT's Return On Assets of -58.35% is in line compared to the rest of the industry. VTVT outperforms 42.81% of its industry peers.
VTVT's Return On Equity of -235.97% is on the low side compared to the rest of the industry. VTVT is outperformed by 69.42% of its industry peers.
Industry RankSector Rank
ROA -58.35%
ROE -235.97%
ROIC N/A
ROA(3y)-96.56%
ROA(5y)-79.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VTVT Yearly ROA, ROE, ROICVTVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

1.3 Margins

VTVT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTVT Yearly Profit, Operating, Gross MarginsVTVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

VTVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
VTVT has more shares outstanding than it did 1 year ago.
VTVT has less shares outstanding than it did 5 years ago.
VTVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VTVT Yearly Shares OutstandingVTVT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VTVT Yearly Total Debt VS Total AssetsVTVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -13.64, we must say that VTVT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VTVT (-13.64) is worse than 78.42% of its industry peers.
There is no outstanding debt for VTVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.64
ROIC/WACCN/A
WACC9.74%
VTVT Yearly LT Debt VS Equity VS FCFVTVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

2.3 Liquidity

A Current Ratio of 7.39 indicates that VTVT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.39, VTVT is in the better half of the industry, outperforming 67.45% of the companies in the same industry.
A Quick Ratio of 7.39 indicates that VTVT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.39, VTVT is in the better half of the industry, outperforming 67.99% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.39
Quick Ratio 7.39
VTVT Yearly Current Assets VS Current LiabilitesVTVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

VTVT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.34%.
Looking at the last year, VTVT shows a very negative growth in Revenue. The Revenue has decreased by -98.30% in the last year.
Measured over the past years, VTVT shows a very negative growth in Revenue. The Revenue has been decreasing by -18.10% on average per year.
EPS 1Y (TTM)-4.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.19%
Revenue 1Y (TTM)-98.3%
Revenue growth 3Y-36.7%
Revenue growth 5Y-18.1%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, VTVT will show a small growth in Earnings Per Share. The EPS will grow by 5.67% on average per year.
Based on estimates for the next years, VTVT will show a very strong growth in Revenue. The Revenue will grow by 112.47% on average per year.
EPS Next Y2.19%
EPS Next 2Y0.14%
EPS Next 3Y-1.31%
EPS Next 5Y5.67%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y112.47%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VTVT Yearly Revenue VS EstimatesVTVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2028 2029 2030 20M 40M 60M 80M
VTVT Yearly EPS VS EstimatesVTVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VTVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VTVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTVT Price Earnings VS Forward Price EarningsVTVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTVT Per share dataVTVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.14%
EPS Next 3Y-1.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VTVT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VTV THERAPEUTICS INC- CL A

NASDAQ:VTVT (7/25/2025, 8:00:01 PM)

15.54

-1.49 (-8.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-07 2025-08-07
Inst Owners22.05%
Inst Owner Change0%
Ins Owners0.72%
Ins Owner Change0%
Market Cap49.57M
Analysts82.5
Price Target36.21 (133.01%)
Short Float %1.08%
Short Ratio2.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.7%
Min EPS beat(2)7.37%
Max EPS beat(2)38.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)3.51%
EPS NQ rev (3m)26.34%
EPS NY rev (1m)10.08%
EPS NY rev (3m)12.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2916.04
P/FCF N/A
P/OCF N/A
P/B 6.26
P/tB 6.26
EV/EBITDA N/A
EPS(TTM)-3.01
EYN/A
EPS(NY)-3.71
Fwd EYN/A
FCF(TTM)-7.42
FCFYN/A
OCF(TTM)-7.42
OCFYN/A
SpS0.01
BVpS2.48
TBVpS2.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.35%
ROE -235.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-96.56%
ROA(5y)-79.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.39
Quick Ratio 7.39
Altman-Z -13.64
F-Score2
WACC9.74%
ROIC/WACCN/A
Cap/Depr(3y)7.41%
Cap/Depr(5y)4.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.19%
EPS Next Y2.19%
EPS Next 2Y0.14%
EPS Next 3Y-1.31%
EPS Next 5Y5.67%
Revenue 1Y (TTM)-98.3%
Revenue growth 3Y-36.7%
Revenue growth 5Y-18.1%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y112.47%
EBIT growth 1Y-5.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.3%
OCF growth 3YN/A
OCF growth 5YN/A